For providing the first evidence that knockdown of TSPAN5 can be used as a therapeutic approach in HCC tumor xenografts, we used a PEI-based delivery platform for TSPAN5 siRNA, thus allowing a therapeutic intervention after the establishment of the tumors. The gene discussed is TSPAN5; the disease is hepatocellular carcinoma.